Indaptus Therapeutics Inc (INDP) USD0.01

Sell:$0.51Buy:$0.54$0.03 (6.35%)

Prices delayed by at least 15 minutes
Sell:$0.51
Buy:$0.54
Change:$0.03 (6.35%)
Prices delayed by at least 15 minutes
Sell:$0.51
Buy:$0.54
Change:$0.03 (6.35%)
Prices delayed by at least 15 minutes

Company Information

About this company

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Key people

Jeffrey A. Meckler
Chief Executive Officer, Director
Nir Sassi
Chief Financial Officer, Treasurer, Secretary
Walt Addison Linscott
Chief Operating Officer
Michael J. Newman
Chief Scientific Officer, Director
Roger J. Waltzman
Chief Medical Officer
Roger J. Pomerantz
Independent Non-Executive Chairman of the Board
Mark J. Gilbert
Independent Director
William Bradley Hayes
Independent Director
Hila Karah
Independent Director
Anthony J. Maddaluna
Independent Director
Click to see more

Key facts

  • EPIC
    INDP
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US45339J1051
  • Market cap
    $7.93m
  • Employees
    7
  • Shares in issue
    14.43m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.